CA3196210A1 - Anticancer compounds selective for er-positive cancers - Google Patents
Anticancer compounds selective for er-positive cancersInfo
- Publication number
- CA3196210A1 CA3196210A1 CA3196210A CA3196210A CA3196210A1 CA 3196210 A1 CA3196210 A1 CA 3196210A1 CA 3196210 A CA3196210 A CA 3196210A CA 3196210 A CA3196210 A CA 3196210A CA 3196210 A1 CA3196210 A1 CA 3196210A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- erso
- dfp
- cancer
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063104933P | 2020-10-23 | 2020-10-23 | |
| US63/104,933 | 2020-10-23 | ||
| PCT/US2021/056003 WO2022087234A1 (en) | 2020-10-23 | 2021-10-21 | Anticancer compounds selective for er-positive cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3196210A1 true CA3196210A1 (en) | 2022-04-28 |
Family
ID=81290080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3196210A Pending CA3196210A1 (en) | 2020-10-23 | 2021-10-21 | Anticancer compounds selective for er-positive cancers |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12655104B2 (enExample) |
| EP (1) | EP4232038A4 (enExample) |
| JP (1) | JP2023546584A (enExample) |
| CN (1) | CN116723841A (enExample) |
| AU (2) | AU2021366688B2 (enExample) |
| CA (1) | CA3196210A1 (enExample) |
| IL (1) | IL302154A (enExample) |
| MX (1) | MX2023004480A (enExample) |
| WO (1) | WO2022087234A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120981469A (zh) * | 2023-02-23 | 2025-11-18 | 晨晖生物科技(香港)有限公司 | 含硼化合物及其治疗用途 |
| WO2026039467A1 (en) * | 2024-08-12 | 2026-02-19 | The Board Of Trustees Of The University Of Illinois | Hydroxyphenyl-indoline-2-one cancer therapeutics |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2855406A (en) | 1955-05-07 | 1958-10-07 | Dann Otto | Preparation of benzopyrans and benzofurans |
| US3773759A (en) | 1972-08-21 | 1973-11-20 | Searle & Co | 1-arylideneamino-4-(2-oxo-3-phenyl-3-benzofuryl)piperazines |
| FR2810320B1 (fr) | 2000-06-19 | 2002-08-23 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| CA2684552A1 (en) * | 2007-04-24 | 2008-10-30 | Topotarget A/S | Substituted 3-(4-hydroxyphenyl)-indolin-2-one compounds |
| EA027139B1 (ru) | 2013-04-26 | 2017-06-30 | Бейджин, Лтд. | Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны |
| CN108440378B (zh) | 2018-03-27 | 2021-03-12 | 宁波大学 | 一种室温下碘-双氧水促进的3-氨基-2-吲哚酮衍生物的制备方法 |
| EP3817741A4 (en) * | 2018-07-03 | 2022-07-06 | The Board of Trustees of the University of Illinois | ACTIVATORS OF THE UNFOLDING PROTEIN RESPONSE |
-
2021
- 2021-10-21 WO PCT/US2021/056003 patent/WO2022087234A1/en not_active Ceased
- 2021-10-21 CA CA3196210A patent/CA3196210A1/en active Pending
- 2021-10-21 US US18/033,173 patent/US12655104B2/en active Active
- 2021-10-21 CN CN202180086814.XA patent/CN116723841A/zh active Pending
- 2021-10-21 EP EP21883881.1A patent/EP4232038A4/en active Pending
- 2021-10-21 IL IL302154A patent/IL302154A/en unknown
- 2021-10-21 MX MX2023004480A patent/MX2023004480A/es unknown
- 2021-10-21 JP JP2023524127A patent/JP2023546584A/ja active Pending
- 2021-10-21 AU AU2021366688A patent/AU2021366688B2/en active Active
-
2026
- 2026-06-02 AU AU2026204244A patent/AU2026204244A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021366688A9 (en) | 2024-06-20 |
| MX2023004480A (es) | 2023-05-04 |
| US12655104B2 (en) | 2026-06-16 |
| EP4232038A4 (en) | 2024-04-10 |
| IL302154A (en) | 2023-06-01 |
| AU2021366688A1 (en) | 2023-05-25 |
| JP2023546584A (ja) | 2023-11-06 |
| EP4232038A1 (en) | 2023-08-30 |
| AU2026204244A1 (en) | 2026-06-18 |
| WO2022087234A1 (en) | 2022-04-28 |
| US20230391721A1 (en) | 2023-12-07 |
| CN116723841A (zh) | 2023-09-08 |
| AU2021366688B2 (en) | 2026-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7662639B2 (ja) | エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用 | |
| KR20220012274A (ko) | 플루오린 함유 화합물 및 이의 항암 의학적 용도 | |
| TWI837402B (zh) | 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途 | |
| JP2022513959A5 (enExample) | ||
| CA2879798C (en) | Procaspase enzyme-activating substituted 2-(4-benzylpiperazin-1-yl)-n'-(2-hydroxybenzylidene)acetohydrazide derivatives and compostions thereof | |
| US20130096133A1 (en) | Procaspase-activating compounds and compositions | |
| JP2024512544A (ja) | テトラヒドロナフタレン系化合物、その製造方法及びその医薬的応用 | |
| US20260103470A1 (en) | Androgen receptor regulation by small molecule enantiomers | |
| CA3103958A1 (en) | Activators of the unfolded protein response | |
| AU2021366688B2 (en) | Anticancer compounds selective for er-positive cancers | |
| US20220089602A1 (en) | Compounds that induce ferroptic cell death | |
| US12312354B2 (en) | Selective BTK irreversible inhibitors | |
| WO2021222738A1 (en) | Compounds for estrogen receptor positive cancers | |
| CN116438177A (zh) | 靶向嵌合化合物、含其的药物组合物及其制备方法和用途 | |
| US11274106B2 (en) | Topoisomerase inhibitors with antibacterial and anticancer activity | |
| WO2026039467A1 (en) | Hydroxyphenyl-indoline-2-one cancer therapeutics | |
| US20250376477A1 (en) | Analgesic delta opioid receptor bitopic ligands | |
| US12552806B2 (en) | Androgen receptor regulation by small molecule enantiomers | |
| WO2025029660A9 (en) | Compounds with selectivity for certain cancers | |
| CN107266468A (zh) | 含吡唑啉结构的噻喃并嘧啶类化合物的制备及应用 | |
| KR101048748B1 (ko) | 신규 갈바닉산 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물 | |
| WO2020210125A1 (en) | Deuterated antimicrobial compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241011 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241011 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251017 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251017 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251017 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251017 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251017 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251217 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251217 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260122 |